Site Editor

David S. Ettinger, MD, FACP, FCCP

Advertisement

Advertisement

News

IASLC 2021: Exploratory Analysis From IMpower010 Trial of Atezolizumab in Resectable NSCLC

News

ESMO 2021: Durvalumab-Based Combinations in COAST Trial of Locally Advanced NSCLC

News

IASLC 2021: CheckMate 907 on De Novo Administration of Nivolumab in Advanced NSCLC

News

FDA Approves Mobocertinib for NSCLC With EGFR Exon 20 Insertion Mutations

News

IASLC 2021: Antibody Response to SARS–CoV-2 Vaccination in Patients With Lung Cancer

News

FDA Approves Mobocertinib for NSCLC With EGFR Exon 20 Insertion Mutations

Medical Literature

Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel in Advanced Lung Cancer

Benjamin Besse, MD, PhD, on Clinical Tips for Prescribing Atezolizumab as Neoadjuvant Therapy for Resectable NSCLC

Martin Reck, MD, PhD, on Dual Immunotherapy Plus Chemotherapy: A Better Way to Treat NSCLC Than Chemotherapy Alone?

View More

Advertisement

JNCCN Spotlights

Dabrafenib + Trametinib (Tafinlar + Mekinist)

Crizotinib (Xalkori)

(UPDATE) Pembrolizumab (Keytruda) in NSCLC

(UPDATE) Nivolumab (Opdivo) in NSCLC

(UPDATE) Afatinib (Gilotrif)

View More

More

News

IASLC 2021: Exploratory Analysis From IMpower010 Trial of Atezolizumab in Resectable NSCLC

Does the Use of Metformin Improve Outcomes in Patients With Non–Small Cell Lung Cancer?

PET/CT Images: Measuring PD-L1 Status and Predicting Response to Immunotherapy in NSCLC

Robotic Bronchoscopy May Improve Timing and Accuracy of Lung Cancer Diagnosis

AXL Inhibitor Bemcentinib Receives Fast Track Designation in Combination Therapy for Lung Cancer

ASCO 2021: EGFR- and MET-Based Biomarkers of Resistance to Therapy for Lung Cancer

ESMO 2021: Durvalumab-Based Combinations in COAST Trial of Locally Advanced NSCLC

Can Postoperative Radiotherapy Improve Survival Outcomes in Patients With NSCLC?

View More

Advertisement

Published

Medical Literature

Can Pan-TRK Immunohistochemistry Identify NTRK Fusions in Lung Cancer?

Larotrectinib for Advanced Lung Cancer With Novel NCOR2-NTRK1 Fusion: Case Study

Brigatinib in Patients With Crizotinib-Refractory ALK-Positive NSCLC

Addition of Selumetinib to Docetaxel in KRAS-Mutant Lung Cancer

View More

Ongoing

CE Activities

Advanced Non-Small Cell Lung Ccancer Patient Management Simulator

Novel and Emerging Therapeutic Strategies in the Management of Non–Small Cell Lung Cancer

Consensus or Controversy? Radiation and Medical Oncology Investigator Perspectives on the Role of Immune Checkpoint Inhibition in the Management of Locally Advanced Non–Small Cell Lung Cancer

Consensus or Controversy? Addressing Practical Clinical Questions Across the Metastatic Lung Cancer Continuum

View More

Available

Clinical Trials

City of Hope Comprehensive Cancer Center

Cleveland Clinic Taussig Cancer Institute

Fox Chase Cancer Center

Fred and Pamela Buffett Cancer Center

View More

Resources

For Your Patients

The American Lung Association

Bonnie J. Addario Lung Cancer Foundation

Caring Ambassadors Program

Dusty Joy Foundation

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2021 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.